Good evening :)
$
₹
IMMUTEP+LTD+SPON+ADS+EACH+REP+200+ORD+SHS

IMMUTEP+LTD+SPON+ADS+EACH+REP+200+ORD+SHS

IMMP

US
Asset Logo

IMMUTEP+LTD+SPON+ADS+EACH+REP+200+ORD+SHS

IMMP

US
$3.234.43% (-0.15)
$
₹
$3.234.43% (-0.15)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $26.3M the stock is ranked 5389

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.88
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-7.3
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 1 analyst's reports

Buy
1 analyst
Hold
0 analyst
Sell
0 analyst

Price Upside

+787.57%

Earnings Growth

—

Rev. Growth

-71.91%

See Detailed Forecast

Company Profile

Company Profile

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma. In addition, the company develops INSIGHT-003, which is in a Phase I trial for 1L non squamous non-small cell lung cancer (NSCLC); EOC 202, which has completed a Phase I trial for metastatic breast cancer; IMP761, an agonist LAG-3 antibody in a Phase I trial; IMP731, a LAG-3 depleting antibody that has completed a Phase II trial for ulcerative colitis and a Phase I trial for psoriasis; and ieramilimab/LAG525/IMP701, which are anti-LAG-3 antagonist antibodies. It has collaborations with Merck & Co., Inc., Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, the Maria Sklodowska-Curie National Research Institute of Oncology, EOC Pharma, Dr Reddy's Laboratories, Monash University, and George Washington University. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma. In addition, the company develops INSIGHT-003, which is in a Phase I trial for 1L non squamous non-small cell lung cancer (NSCLC); EOC 202, which has completed a Phase I trial for metastatic breast cancer; IMP761, an agonist LAG-3 antibody in a Phase I trial; IMP731, a LAG-3 depleting antibody that has completed a Phase II trial for ulcerative colitis and a Phase I trial for psoriasis; and ieramilimab/LAG525/IMP701, which are anti-LAG-3 antagonist antibodies. It has collaborations with Merck & Co., Inc., Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, the Maria Sklodowska-Curie National Research Institute of Oncology, EOC Pharma, Dr Reddy's Laboratories, Monash University, and George Washington University. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
77.50
77.50
1Y Return
20.6%
20.6%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
25.64
25.64
1Y Return
41.49%
41.49%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.59%
29.59%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
28.09
28.09
1Y Return
20.93%
20.93%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
762.09%
762.09%
Buy Reco %
21.73
21.73
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 787.57% growth, versus a trailing 3-year CAGR of -54.72%.

2026
Current$3.38Baseline
Analyst Target - 1 year
Target$30+787.57%

All values in $

202220232024202520262027$18.01$32.98$47.95Target+787.57%
2026
Current$3.38Baseline
Analyst Target - 1 year
Target$30+787.57%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -71.91% growth, versus a trailing 3-year CAGR of 59.55%.

2026
Current$14.23Baseline
Forecast for Jun 2027
High$4-71.91%
Average$4-71.91%
Low$4-71.91%

All values in $ Million

2022202320242025202620270.173.503.845.0414.23Low-71.91%Average-71.91%High-71.91%
2026
Current$14.23Baseline
Forecast for Jun 2027
High$4-71.91%
Average$4-71.91%
Low$4-71.91%

All values in $ Million

Financials

Financials

Income

Balance Sheet

Cash Flow

1.8
-39
6
-44.8
10.6
-34.9
Q2 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q4 2025Q1 2026Q2 2026
Total Revenue2.11-1.731.733.14-1.896.02-10.62
Net Income-21.22--21.48-21.48-22.37--39.05-44.85--34.93
Net Profit Margin-1005.72%--1241.29%-1241.29%-710.92%--2059.84%-744.35%--328.77%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
IMMUTEP+LTD+SPON+ADS+EACH+REP+200+ORD+SHS -0.88-
AbbVie Inc77.5050.450.54
Amgen Inc25.6418.782.45
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare IMMP with any stock or ETF
Compare IMMP with any stock or ETF
Comparing from
IMMP
ABBV
AMGN
Loading...

Frequently asked questions

  1. IMMUTEP+LTD+SPON+ADS+EACH+REP+200+ORD+SHS (IMMP) share price today is $3.23 as of October 15, 2026 at 7:23 PM IST. The stock touched a day high of $3.23 and a day low of $3.17.

  2. IMMUTEP+LTD+SPON+ADS+EACH+REP+200+ORD+SHS stock trades on US under the ticker symbol IMMP.

  3. IMMUTEP+LTD+SPON+ADS+EACH+REP+200+ORD+SHS's market capitalization is $26.3M as of October 15, 2026 at 7:23 PM IST.

  4. IMMUTEP+LTD+SPON+ADS+EACH+REP+200+ORD+SHS's price-to-earnings (P/E) ratio is N/A as of October 15, 2026.

  5. IMMUTEP+LTD+SPON+ADS+EACH+REP+200+ORD+SHS's price-to-book (P/B) ratio is 0.88 as of October 15, 2026.

  6. Yes, You can buy IMMUTEP+LTD+SPON+ADS+EACH+REP+200+ORD+SHS shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy IMMUTEP+LTD+SPON+ADS+EACH+REP+200+ORD+SHS shares in three steps: 1. Search IMMUTEP+LTD+SPON+ADS+EACH+REP+200+ORD+SHS on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since IMMUTEP+LTD+SPON+ADS+EACH+REP+200+ORD+SHS trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in IMMUTEP+LTD+SPON+ADS+EACH+REP+200+ORD+SHS (IMMP) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 3.0959 shares at the current price of $3.23.

Loading...